Lung Post-Transplant Monitoring Health Economics: The Lung Allograft Rejection Gene Expression Observational (LARGO) Study
Client: XDx, Inc., Brisbane, California
- XDx, Inc. is pursuing the development and commercialization of a molecular diagnostic test that improves the management of lung transplant patients. The non-invasive diagnostic test identifies the presence or absence of acute cellular rejection (ACR) based on empirical insights into the molecular mechanisms which regulate tissue rejection. XDx is also exploring the potential influence of host responses to infection on peripheral blood gene expression profiles for ACR.
- In order to determine pricing and support product reimbursement strategy, an accurate assessment of the health economics of current standard of care post-transplant monitoring and diagnosis is necessary. As currently conceived, the XDx lung molecular diagnostic test will replace and/or complement existing rejection and infection diagnostic procedures, namely bronchoscopy, bronchoalveolar lavage, and transbronchial lung biopsy.